Last reviewed · How we verify
Bay 59-8862
Bay 59-8862 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Bay 59-8862 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | Bay 59-8862 |
|---|---|
| Sponsor | Bayer |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, Bay 59-8862 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism of action is associated with several potential benefits, including improved glycemic control and weight loss.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer (PHASE2)
- An Efficacy Study Of Ortataxel In Recurrent Glioblastoma (PHASE2)
- Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients (PHASE2)
- Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma (PHASE2)
- Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (PHASE2)
- Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients (PHASE2)
- BAY 59-8862 in Treating Patients With Advanced Kidney Cancer (PHASE2)
- BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bay 59-8862 CI brief — competitive landscape report
- Bay 59-8862 updates RSS · CI watch RSS
- Bayer portfolio CI